Osimertinib to Overcome the Challenge of Developing Resistance in the Patients Suffering from NSCLC

Release Date: 24-Nov-2020

A novel study points out the significant benefits that is delivered through epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the patients suffering from non-small cell lung cancer patients and having EGFR-activating mutations. It has been found that the resistance developed by the patients leads to certain limitations in the long-term efficacy. Therefore, altogether it requires urgent discovery of a mechanism that could develop strategy against overcoming such resistance in the patients with respect to EGFR TKIs.

The novel clinical trial conducted by the researchers is to determine the whole mechanism that is underlying the resistance developed in case of non-small cell lung cancer to the drug Osimertinib. It was analyzed by the researchers that level of two proteins Bcl-2 as well as Bcl-xl was regulated in the cells that have developed resistance when compared with the other cells. It was concluded by the researchers that the overall combined treatment of the patients with ABT‑263 and Osimertinib led to an increased rate of cell apoptosis as well as mitochondrial apoptotic pathway. In the last, the investigational drug ABT‑263 was able to end the resistance in the xenograft tumor models with respect to Osimertinib. According to the researchers involved in the respective study, this novel concept of overcoming resistance could be highly responsible for transforming the entire cancer therapeutics market.